HA

Hanseatic Asset Management

Europe, England, United Kingdom, London

Description

Hanseatic Asset Management is a Comprehensive investment management and advisory service to global investors.

Investor Profile

Hanseatic Asset Management has backed more than 3 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 1 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series Unknown, Private Equity, Series G rounds (top funding stages).
  • Majority of deals are located in Germany, United States.
  • Strong thematic focus on Biotechnology, Medical, Therapeutics.

Stage Focus

  • Series Unknown (33%)
  • Private Equity (33%)
  • Series G (33%)

Country Focus

  • Germany (67%)
  • United States (33%)

Industry Focus

  • Biotechnology
  • Medical
  • Therapeutics
  • Health Care
  • Pharmaceutical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Hanseatic Asset Management frequently co-invest with?

HP
Europe, Baden-Wurttemberg, Germany, Heidelberg
Co-Investments: 2
BR
North America, California, United States, San Francisco
Co-Investments: 1
Morgan Stanley Venture Partners
North America, New York, United States, New York
Co-Investments: 1
Credit Suisse
North America, North Carolina, United States, Morrisville
Co-Investments: 1
BG
Europe, England, United Kingdom, London
Co-Investments: 1
Warburg Pincus
Europe, Madrid, Spain, Boadilla Del Monte
Co-Investments: 1
Alta Partners
North America, Mississippi, United States, Jackson
Co-Investments: 1
Bayern Kapital
Europe, Bayern, Germany, Landshut
Co-Investments: 2
GeneChem
North America, Quebec, Canada, Montréal
Co-Investments: 1
Moore Capital
North America, New York, United States, New York
Co-Investments: 1

What are some of recent deals done by Hanseatic Asset Management?

Vasopharm

Würzburg, Bayern, Germany

Vasopharm is focused on the R&D of novel therapeutics for the treatment of cerebro and cardiovascular diseases and their symptoms.

BiotechnologyMedicalTherapeutics
Private EquityJul 11, 2019
Amount Raised: $10,687,306
Vasopharm

Würzburg, Bayern, Germany

Vasopharm is focused on the R&D of novel therapeutics for the treatment of cerebro and cardiovascular diseases and their symptoms.

BiotechnologyMedicalTherapeutics
Series GJan 21, 2016
Amount Raised: $21,737,500
The Medicines Company

Parsippany, New Jersey, United States

The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective

BiotechnologyHealth CarePharmaceutical
Series UnknownJan 1, 1999

Find More Investors Like Hanseatic Asset Management

Discover similar investors in our database and build your perfect investor list.

Need help with your fundraising strategy?Read our fundraising guides

Hanseatic Asset Management | Pipeseed